ライフサイエンスコーパス: non-muscle

1 ephosphorylates the RLC in smooth muscle and non-muscle.

2 Here, we demonstrate that the non-muscle ~214-kDa myosin light chain (MLC) kinase (nmM

3 to rabbit skeletal muscle (alpha) and human non-muscle (85% beta, 15% gamma) actin filaments from th

4 That non-muscle acidic calponin interacts with caldesmon with

5 inst a human cDNA library and identified the non-muscle actin filament cross-linking protein filamin

6 When non-muscle actin is used, FRLalpha-C's effects are large

7 a(cyto)-actin can likely build all essential non-muscle actin-based cytoskeletal structures including

8 erent from that of filaments containing beta-non-muscle actin.

9 governing the specification and function of non-muscle actomyosin structures, such as contractile ri

10 pically co-express ACTN4 and ACTN1, a second non-muscle alpha-actinin gene.

11 stoma cell variants which encodes the second non-muscle alpha-actinin isoform designated ACTN4 (actin

12 Recombinant TM5a, a short non-muscle alpha-tropomyosin, inhibited depolymerization

13 tribution of CeMyoD to specification of both non-muscle and muscle fates.

14 Unlike most vertebrate non-muscle and smooth muscle myosin IIs, baculovirus-exp

15 The interaction of profilin and non-muscle beta,gamma-actin prepared from bovine spleen

16 Here, we examine the role of "non-muscle" caveolins (Cav-1 and Cav-2) in skeletal musc

17 Non-muscle cell contractility is critical for tissues to

18 step in the initiation of smooth muscle and non-muscle cell contraction.

19 other SH3-containing proteins in muscle and non-muscle cell extracts were validated with peptide arr

20 n cell lineages are normally established and non-muscle cell fate markers begin to be expressed.

21 ssion of c6orf32 in C2C12 or HEK293 cells (a non-muscle cell line) promoted formation of long membran

22 nd differentiation of the diverse muscle and non-muscle cell lineages of the heart.

23 iadin-1 as a series of glycoform variants in non-muscle cell lines and neonatal heart cells using pla

24 nsitization of smooth muscle contraction and non-muscle cell motility is through inhibition of the sm

25 ity without transdifferentiation to multiple non-muscle cell types and tested dystrophin restoration

26 In non-muscle cell types, lysosomes are critical mediators

27 cle terminal differentiation in a variety of non-muscle cell types, MyoD activity itself is highly re

28 and smooth muscle differentiation markers in non-muscle cell types.

29 ed muscles, 16 non-striated muscles, and two non-muscle cells (coelomocytes).

30 sassembly of the actin-based cytoskeleton in non-muscle cells and clears the circulation of filaments

31 for global actin cytoskeleton remodeling in non-muscle cells and provide insight into cellular respo

32 s the presence of a skelemin-like protein in non-muscle cells and provides evidence that it may be in

33 lso binds to F-actin in smooth muscle and in non-muscle cells and stabilizes and regulates the filame

34 Adhesion and morphogenesis of many non-muscle cells are guided by contractile actomyosin bu

35 ac myocytes, C2C12 myotubes, and transfected non-muscle cells expressing alpha1 subunits.

36 fferentiated skeletal muscle (myoblasts) and non-muscle cells in culture.

37 ed by exon 9d expressed in smooth muscle and non-muscle cells increases the affinity of unacetylated

38 division of mesodermal cells into muscle and non-muscle cells is crucial to animal development.

39 normally in muscle cells and ectopically in non-muscle cells is dependent upon the integrity of the

40 Non-muscle cells that expressed alpha(v) and beta1 integ

41 new regulatory pathway in smooth muscle and non-muscle cells whereby ROCK1 phosphorylates and regula

42 In non-muscle cells, a shorter CaD isoform co-exists with m

43 ulate the contractility of smooth muscle and non-muscle cells, and there is evidence that this occurs

44 n mouse myogenic cells, we found that, as in non-muscle cells, Bax co-immunoprecipitated with the mul

45 activity of myosin II, in smooth muscle and non-muscle cells, by modulating the Ca2+ sensitivity of

46 In non-muscle cells, CHC22 localizes to perinuclear vesicul

47 al component of caveolae membrane domains in non-muscle cells, including mammary epithelia.

48 t high levels in muscle and at low levels in non-muscle cells, relative to CHC17.

49 the major intracellular reservoir of Ca2+ in non-muscle cells, sequestering Ca2+ for use in intracell

50 induce myogenic differentiation in cultured non-muscle cells, suggesting that they might be function

51 myosin (RLC) controls motility of mammalian non-muscle cells, the functional significance of RLC pho

52 to caffeine and halothane when expressed in non-muscle cells, their influence on EC coupling can onl

53 wo mutations inhibit myosin self-assembly in non-muscle cells, they do not prevent incorporation of t

54 ogene has been shown to induce myogenesis in non-muscle cells, to promote muscle hypertrophy in postn

55 In non-muscle cells, tropomyosin additionally controls acce

56 Among multiple TMs expressed in non-muscle cells, tropomyosin-1 (TM1) isoform induces st

57 In smooth muscle and non-muscle cells, where troponin is absent, the precise

58 olin-1 is required for caveolae formation in non-muscle cells, while the expression of caveolin-3 dri

59 l building blocks of the cytoskeleton in all non-muscle cells.

60 functional roles of actomyosin in muscle and non-muscle cells.

61 length of actin filaments in both muscle and non-muscle cells.

62 ), and is also associated with cell cycle in non-muscle cells.

63 ochemical characteristics of both muscle and non-muscle cells.

64 by rapid cytoskeletal rearrangement, even in non-muscle cells.

65 d for different actin dynamics in muscle and non-muscle cells.

66 -calponin is found in both smooth muscle and non-muscle cells.

67 activate this enhancer in some, but not all, non-muscle cells.

68 pha-MHC gene by preventing its expression in non-muscle cells.

69 s a silencer of alpha-MHC gene expression in non-muscle cells.

70 iation program when ectopically expressed in non-muscle cells.

71 tural basis of its functioning in muscle and non-muscle cells.

72 cle cells, despite substantial DNA uptake by non-muscle cells.

73 ntraction and other contractile processes in non-muscle cells.

74 ecting a subset of both striated muscles and non-muscle cells.

75 ed muscles, 16 non-striated muscles, and two non-muscle cells.

76 ion of mouse AChR subunits and calnexin into non-muscle cells.

77 nt mechanism for the activation of myosin in non-muscle cells.

78 nd MEF2C stimulate RGMc promoter function in non-muscle cells.

79 the mechanical function of alpha-actinin in non-muscle cells: alpha-actinin-microinjected cells are

80 an myosin complement have been identified as non-muscle class II myosins.

81 formation of striated body wall muscles and non-muscle coelomocytes.

82 Non-muscle contraction is widely believed to be mediated

83 scence microscopy, we show that tropomyosin (non-muscle Drosophila Tm1A) polymerizes along actin fila

84 To investigate the function of the major non-muscle dystrophin isoform, Dp71, we substituted a be

85 anslationally active in Escherichia coli and non-muscle eukaryotic cells, producing the expected trun

86 whether a striated muscle exon 9a or smooth/non-muscle exon 9d is present.

87 and stimulates inclusion of the alternative non-muscle exon.

88 differ internally by exons 6a/6b and possess non-muscle exons 1b/9d at the termini, hence they lack t

89 study we cloned and characterized muscle and non-muscle factors that bind to this element.

90 A-1, function synergistically to promote the non-muscle fate in cells also competent to form muscles.

91 aling, whereas 21 proteins, including myosin non-muscle form A, annexin 2, annexin A6, and Hsp47 were

92 found in the ocular primordia and muscle and non-muscle forming tissues of the eyes.

93 Introduction of the non-muscle Galphas isoform, GalphasXL elicited hypertrop

94 Six point mutations in non-muscle gamma-actin at the DFNA20/26 locus cause auto

95 enes targeted by miR-200a, we focused on the non-muscle heavy chain IIb (NMHCIIb), and showed that mi

96 protein markers may have prognostic value in non-muscle invasive bladder cancer for guiding optimal t

97 nother six patients (14%) were downstaged to non-muscle invasive disease.

98 ive multi-center transcriptional analysis of non-muscle invasive urothelial bladder cancer.

99 three different tissue microarrays with 693 non-muscle invasive urothelial carcinomas from Danish, S

100 er cancer with worse clinical prognosis from non-muscle-invasive (superficial) cancer, has significan

101 he primary tumor site showed no (T0) or only non-muscle-invasive (T1) residual tumor.

102 muscle-invasive (T2-T4 stage) compared with non-muscle-invasive (Ta, T1 stage) bladder cancer (case-

103 dder cancer and can be categorized as either non-muscle-invasive (Ta-T1) or muscle-invasive (T2).

104 The majority of bladder cancers are non-muscle-invasive at presentation; however, the recurr

105 To assess effect on recurrence, we grouped non-muscle-invasive BC patients according to intravesica

106 In patients with non-muscle-invasive BC, the variant IL-6 genotype was as

107 Purpose Many patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are either re

108 med the overexpression of fibulin-3 in T2 vs non-muscle-invasive bladder cancer (NMIBC) by quantitati

109 Non-muscle-invasive bladder cancer (NMIBC) is a highly r

110 Patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) without carci

111 recurrence and progression in patients with non-muscle-invasive bladder cancer (NMIBC).

112 Non-muscle-invasive bladder cancer embraces a spectrum o

113 For non-muscle-invasive bladder cancer, the mainstay of trea

114 ladder cancer is the highest risk subtype of non-muscle-invasive bladder cancer, with highly variable

115 CR) gene signature to predict progression in non-muscle-invasive bladder cancer.

116 s the surgical mainstay for the treatment of non-muscle-invasive bladder cancer.

117 ne QPCR panel to help predict progression of non-muscle-invasive bladder cancers and delineate a syst

118 ict the progression of a subset of recurring non-muscle-invasive cancers.

119 and 10-year estimates of muscle-invasive LF, non-muscle-invasive LF, and DM were 13% and 14%, 31% and

120 specific survival (DSS), muscle-invasive and non-muscle-invasive local failure (LF), and distant meta

121 d for carcinoma in situ and other high grade non-muscle-invasive tumours.

122 th bladder tumors (either muscle-invasive or non-muscle-invasive).

123 Dp116 is a non-muscle isoform of dystrophin that assembles the dyst

124 The ADF-like non-muscle isoform UNC-60A had greater activities to cau

125 n platelets is identical to the cytoskeletal/non-muscle isoform.

126 domain in Ca(2+)-dependent actin binding of non-muscle isoforms.

127 smooth muscle-specific caldesmon (h-CaD) and non-muscle (l-CaD) by Western blotting, RT-PCR, and real

128 r dystrophy, little is known regarding their non-muscle lineage choices or whether the dystrophic mus

129 Actin, Troponin I, and Myosin Light Chain in non-muscle lineages.

130 the specification and differentiation of the non-muscle mesodermal cells, the coelomocytes (CCs).

131 tivation did not affect cell contribution to non-muscle mesodermal lineages, including fibroblasts an

132 ctin-linked' regulation of smooth muscle and non-muscle Mg(2+) actin-activated myosin II ATPase activ

133 This study addressed the role of non-muscle myosin (NM) IIA in two different modes of epi

134 smooth muscle (to regulate contraction) and non-muscle myosin (to regulate non-apoptotic cell death)

135 ccumulate different amounts of active apical non-muscle myosin 2 depending on the distance from the v

136 Additionally, blocking Rho and non-muscle myosin attenuated MT1-MMP-induced phenotypic

137 Here we show the identification of non-muscle myosin heavy chain 9 (MYH9) as an essential f

138 en a candidate gene in this region, encoding non-muscle myosin heavy chain A (MYH9), for mutations in

139 gene-trapped ES cell lines specific for the non-muscle myosin heavy chain class IIA or myosin heavy

140 Mass spectrometry analysis revealed that non-muscle myosin heavy chain II A (NMHC IIA) is a prote

141 al cell-specific alternative splicing of the non-muscle myosin heavy chain II-B pre-mRNA as a model.

142 ive splicing of a cassette exon, N30, in the non-muscle myosin heavy chain II-B pre-mRNA, previously

143 associated with rat liver mitochondrial DNA: non-muscle myosin heavy chain IIA and beta-actin.

144 radient analysis suggest some beta-actin and non-muscle myosin heavy chain IIA reside within human mi

145 , transient gene silencing of MYH9 (encoding non-muscle myosin heavy chain IIA), or the closely relat

146 or the closely related MYH10 gene (encoding non-muscle myosin heavy chain IIB), altered the topology

147 n (MLC), and the IIA and IIB isoforms of the non-muscle myosin heavy chain in rat IMCD cells.

148 Cs and intact CPAs expressed h-caldesmon and non-muscle myosin heavy chain-2; phenotypic markers of c

149 cells polarize to anisotropic features under non-muscle myosin II (MII) inhibition, despite MII ordin

150 s, this remodelling requires the activity of non-muscle myosin II (MyoII) in the interphasic cells ne

151 ired to power these changes are generated by non-muscle myosin II (MyoII) motor proteins pulling fila

152 proteins that triggers rapid and reversible non-muscle myosin II (NM II) dependent contraction of th

153 the neuroepithelium is tightly regulated by non-muscle myosin II (NMII) activity, we tested the role

154 Inhibition of non-muscle myosin II (NMII) enhances central but impairs

155 s establishes the critical role of ezrin and non-muscle myosin II (NMII) in the progressive implement

156 Non-muscle myosin II (NMII) is a conserved force-produci

157 Non-muscle myosin II (NMII) is reported to play multiple

158 lls, this process depends on the activity of non-muscle myosin II (NMII), a family of actin-binding m

159 that treatment with a specific inhibitor of non-muscle myosin II (NMII), blebbistatin, enhances the

160 ile forces generated by the molecular motor, non-muscle myosin II (NMII).

161 t localization of both canonical anillin and non-muscle myosin II (NMM-II) to intercellular bridges.

162 dentified an interaction between CLPTM1L and non-muscle myosin II (NMM-II), a protein involved in mai

163 Here we have investigated the role of non-muscle myosin II (nmy-2) in these asymmetric divisio

164 Interfering with non-muscle myosin II (referred to as Myosin II) activity

165 Inhibition of non-muscle myosin II also resulted in a disruption of ME

166 Additionally, we show that non-muscle Myosin II and the polarity proteins Discs lar

167 Particularly, we identified non-muscle myosin II as an important factor in Kv2.1 tra

168 evidence for an involvement of cadherins and non-muscle myosin II as downstream components controllin

169 tension of actin cytoskeleton by inhibiting non-muscle myosin II ATPase decreased h2-calponin expres

170 e events requires that vertebrate smooth and non-muscle myosin II can achieve an "off" state.

171 Here we show that non-muscle myosin II has a direct role in actin network

172 ence of the entire zipper gene, that encodes non-muscle myosin II heavy chain (MHC) in Drosophila mel

173 lls, and reacted on Western blots with a pan-non-muscle myosin II heavy chain antiserum.

174 able to substitute partially for endogenous non-muscle myosin II heavy chain in animals lacking zygo

175 ant phenotypes when introduced into the sole non-muscle myosin II heavy chain in Drosophila melanogas

176 nsfer assay, that assembly of the Drosophila non-muscle myosin II heavy chain, zipper, is mediated by

177 data indicate a high degree of identity with non-muscle myosin II heavy chain.

178 Although, the non-muscle myosin II holoenzyme (myosin) is a molecular

179 naling in IMCD cells and point to a role for non-muscle myosin II in regulation of water permeability

180 The motor protein non-muscle myosin II is a major driver of the movements

181 The activity of smooth muscle/non-muscle myosin II is regulated by phosphorylation of

182 Non-muscle myosin II is shown to be expressed in a patte

183 Two of the three human non-muscle myosin II isoforms (IIA and IIB) have been in

184 Non-muscle myosin II isoforms thus appear to have distin

185 In spite of the presence of multiple non-muscle myosin II isoforms, we demonstrate that a sin

186 hanisms of wild-type and the S237C mutant of non-muscle myosin II motor from Dictyostelium discoideum

187 th increasing shear stress and inhibition of non-muscle myosin II motors, respectively.

188 horylation and signalling cascade, including non-muscle myosin II redistribution and co-localization

189 ant heavy chains resulted in D. melanogaster non-muscle myosin II with partial wild-type function.

190 These data reveal that the activity of non-muscle myosin II, a critical molecule of cellular co

191 atively regulates the mono-ubiquitination of non-muscle Myosin II, a protein associated with hearing

192 Here, we show that non-muscle myosin II, alpha-actinin, and filamin accumul

193 genesis depends on the correct regulation of non-muscle Myosin II, but how this motor protein is spat

194 n (RLC) phosphorylation activates smooth and non-muscle myosin II, but it has not been established if

195 We find that a single non-muscle myosin II, NMIIB, is required for meiotic cyt

196 re known to express at least two isoforms of non-muscle myosin II, referred to as myosin IIA and myos

197 veral features in common with known forms of non-muscle myosin II, the distinctly unconventional feat

198 e midzone (midzone MTs), whereas F-actin and non-muscle myosin II, together with other factors, organ

199 r apicomedial accumulation of Rho kinase and non-muscle myosin II, which coordinate apical constricti

200 Myh9, the non-muscle myosin II-A heavy chain, was enriched in immu

201 e interaction of RLC with the neck region of non-muscle myosin II-B (NMII-B) heavy chain; NR-RLC inte

202 We report a novel isoform of non-muscle myosin II-C (NM II-C), NM II-C2, that is gene

203 light chain kinase (MLCK) and regulation of non-muscle myosin II.

204 gh its ability to phosphorylate and activate non-muscle myosin II.

205 ulating cortical actomyosin activity through non-muscle myosin II.

206 We identify the heavy chain of the non-muscle myosin IIA (NMHC-IIA) as being phosphorylated

207 and results in the S1943 phosphorylation of non-muscle Myosin IIA (NMIIA) heavy chain, thus facilita

208 ase (MLCK), culminating in the activation of non-muscle myosin IIA (NMIIA).

209 ut increases the interaction of C2GnT-M with non-muscle myosin IIA and its transportation to the endo

210 +) supplementation or chemical inhibition of non-muscle myosin IIA heavy chain activity.

211 e report the kinetic characterization of the non-muscle myosin IIA isoform.

212 s, alpha-actinin cross-linking proteins, and non-muscle myosin IIA mini-filaments.

213 Similar to non-muscle myosin IIB, non-muscle myosin IIA shows high ADP affinity and little

214 This implies that non-muscle myosin IIA spends only a small fraction of it

215 MYH9 encodes the heavy chain of non-muscle myosin IIA, a cellular motor involved in moti

216 e Giantin site and is recycled by binding to non-muscle myosin IIA, a motor protein, via the cytoplas

217 ine TM cells contained Plectin 1, Filamin A, non-muscle myosin IIA, clathrin, alpha-actinin, vimentin

218 Non-muscle myosin IIB (NMIIB) generates tension along ac

219 hed new light on the mechanism, showing that non-muscle myosin IIb is intimately involved.

220 Transient kinetics of non-muscle myosin IIB showed that this motor has a very

221 port the kinetic characterization of a human non-muscle myosin IIB subfragment-1 construct produced i

222 Thus, non-muscle myosin IIB subfragment-1 spends a significant

223 In contrast, genetic ablation of non-muscle myosin IIB was associated with a 60% decrease

224 Similar to non-muscle myosin IIB, non-muscle myosin IIA shows high

225 al protein kinase C, a negative regulator of non-muscle myosin IIB.

226 actin-bound states, which is in contrast to non-muscle myosin IIB.

227 The role for non-muscle myosin in cell motility was controversial, bu

228 nset of the establishment phase involves the non-muscle myosin NMY-2 and the 14-3-3 protein PAR-5.

229 ents of muscle myosin subfragment 1 (S1) and non-muscle myosin V (MV).

230 lasts that were immunoreactive for vimentin, non-muscle myosin, and fibronectin, but not for alpha-sm

231 /3 or its activators changes the dynamics of non-muscle myosin, NMY-2, and alters the cortical accumu

232 hain, desmin, vinculin, and laminin, but not non-muscle myosin, vimentin, fibronectin, or type IV col

233 e contraction of a circumferential actin and non-muscle myosin-II (myosin) belt underlying adherens j

234 rturbations of INM by inhibition of actin or non-muscle myosin-II (NMII) reduced INM measures.

235 d that heavy chain phosphorylation regulates non-muscle myosin-II assembly in an isoform-specific man

236 g associated with an apical concentration of non-muscle myosin.

237 Cytoplasmic (or non-muscle) myosin II isoforms are widely expressed mole

238 UNC-45A is a molecular chaperone targeted to non-muscle myosins and is essential for cell division.

239 osins have general relevance for cardiac and non-muscle myosins as well as for skeletal muscle.

240 Kinetic adaptation of muscle and non-muscle myosins plays a central role in defining the

241 tely inactive state of vertebrate smooth and non-muscle myosins.

242 e a strain-sensitive step in many muscle and non-muscle myosins.

243 few examples of postsynaptic function for a non-muscle nicotinic acetylcholine receptor (nAChR).

244 KEY POINTS: Non-muscle (NM) and smooth muscle (SM) myosin II are bot

245 ABSTRACT: The molecular function of non-muscle (NM) isoforms of myosin II in smooth muscle (

246 tile cardial cells (CCs) and the surrounding non-muscle pericardial cells (PCs), development of which

247 t express others, and in addition, express a non-muscle protein.

248 tile markers and appearance of expression of non-muscle proteins ("proliferative phenotype").

249 asts (Mb), myotubes (Mt), muscle and diverse non-muscle samples to elucidate the involvement of multi

250 transcription of muscle genes in a range of non-muscle somatic cell nuclei after transplantation to

251 They cause muscle genes of nuclei from non-muscle somatic cells, after injection into oocytes,

252 Myosin 2 from vertebrate smooth muscle or non-muscle sources is in equilibrium between compact, in

253 d tropomyosin isoforms, from both muscle and non-muscle sources, was investigated.

254 ces between the skeletal-muscle-specific and non-muscle-specific frequency matrices for the binding s

255 bunits (VIa, VIIa, and VIII) have muscle and non-muscle-specific isoforms, subunit IV contains a lung

256 Non-muscle-specific promoters are produced when the sequ

257 if are removed or modified to match those of non-muscle-specific promoters such as the simian virus 4

258 AT elements mediate both muscle-specific and non-muscle-specific transcription.

259 ad functional attenuation of both muscle and non-muscle symptoms.

260 icated in the onset of insulin resistance in non-muscle tissue.

261 nin in the extracellular matrix, its role in non-muscle tissues remains elusive.

262 Non-muscle tissues that are sensitive to TH, such as the

263 gfp expression was never observed in non-muscle tissues using the MLC-GFP construct.

264 However, gene transfer in non-muscle tissues, mainly the liver, was dramatically r

265 functions have been ascribed to myoferlin in non-muscle tissues.

266 act independently of dystrophin/utrophin in non-muscle tissues.

267 the manifestations of myotonic dystrophy in non-muscle tissues.

268 orms, their promoters and role in muscle and non-muscle tissues.

269 erving intracellular Ca2+ signaling pools in non-muscle tissues; however, unlike the ubiquitous SERCA

270 e highly conserved N termini of three short, non-muscle TMs (alpha, gamma, delta-TM) for the two Tmod

271 dependence of this movement, suggesting that non-muscle tropomyosin isoforms exist, at least in part,

272 important N terminus of a short 247-residue non-muscle tropomyosin was determined in an engineered c

273 ion of the high molecular weight isoforms of non-muscle tropomyosin.